Sign in

CIK 0001761612 · Non-accelerated filer<br>Smaller reporting company

BICYCLE THERAPEUTICS PLC

Sign in to watch
Ticker
BCYC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
United Kingdom
Entity type
operating
Phone
011441223261503
Business address
BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, United Kingdom, CB21 6GS
Former names
BICYCLE THERAPEUTICS Ltd
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$64,039
in 7 filings, $7K under 10b5-1 plans

Net −$64,039. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Lee Kevin −$27K CHIEF EXECUTIVE OFFICER sold 1% of stake
  2. Swanton Robert Charles −$12K Director sold 18% of stake
  3. Skynner Michael −$9K CHIEF SCIENTIFIC OFFICER sold 2% of stake
  4. Perry Jennifer Scott −$7K Chief Operating Officer sold 2% of stake
  5. Hannay Michael Charles Ferguson −$6K CHIEF PROD & SUPPLY CHAIN OFF sold 2% of stake
Date Insider Transaction Shares Price Value Owned after
2019-05-28 BINGHAM KATE Director Purchase +377,732 $14.00 $5.3M 1,875,637
2019-05-28 BINGHAM KATE Director Purchase +7,983 $14.00 $112K 39,637
2019-05-28 BINGHAM KATE Director Conversion · Series A Preferred Shares −874,709 0
2019-05-28 BINGHAM KATE Director Conversion · Series B1 Preferred Shares −623,196 0
2019-05-28 BINGHAM KATE Director Conversion · Series A Preferred Shares −18,485 0
2019-05-28 BINGHAM KATE Director Conversion · Series B1 Preferred Shares −13,169 0
2019-05-28 HARLAND DEBORAH Director Conversion +893,195 893,195
2019-05-28 HARLAND DEBORAH Director Conversion +636,366 1,529,561
2019-05-28 HARLAND DEBORAH Director Purchase +385,714 $14.00 $5.4M 1,915,275
2019-05-28 HARLAND DEBORAH Director Conversion · Series A Preferred Shares −893,195 0
2019-05-28 HARLAND DEBORAH Director Conversion · Series B1 Preferred Shares −636,366 0
2019-05-28 Legault Pierre Director Grant or award · Stock Option (Right to Buy) +116,827 116,827
2019-05-28 Lee Kevin Chief Executive Officer Grant or award · Stock Option (Right to Buy) +506,252 506,252
2019-05-28 Leone Peter Brian Chief Business Officer Grant or award · Stock Option (Right to Buy) +43,269 43,269
2019-05-28 Kalowski Lee President and CFO Grant or award · Stock Option (Right to Buy) +283,414 283,414
2019-05-28 Skynner Michael Chief Operating Officer Grant or award · Stock Option (Right to Buy) +183,895 183,895
2019-05-28 Keen Nicholas Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +177,404 177,404
2019-05-28 GLAXOSMITHKLINE PLC Director Conversion +893,195 893,195
2019-05-28 GLAXOSMITHKLINE PLC Director Conversion +636,366 1,529,561
2019-05-28 GLAXOSMITHKLINE PLC Director Purchase +385,714 $14.00 $5.4M 1,915,275

Page 33 of 34 · 664 trades